Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04826705
Other study ID # the PROMISING Study
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 1, 2021
Est. completion date February 1, 2027

Study information

Verified date December 2023
Source Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

There have been a number of randomized controlled studies (RCT) showing the efficacy of the endovascular treatment with drug-coated balloons (DCB) in the femoropopliteal artery lesions. However, these studies have been carefully designed, and most of them have excluded long-length lesions and severely calcified lesions. In addition to being used alone in the real word, drug-coated balloons (DCB) are also used in combination with stents or debulking devices, but in these randomized controlled studies (RCT) they are only compared with standard percutaneous transluminal angioplasty (PTA). Therefore, the investigators initiated this study, which is a prospective, multicenter, observational real-world study of short and long-term outcome in endovascular treatment of femoropopliteal arterial occlusive lesions with DCB.


Description:

Traditional endovascular approaches to the treatment of atherosclerotic disease in the femoropopliteal arteries include percutaneous transluminal angioplasty (PTA) with an uncoated balloon and implantation of a bare metal stent. Recently, drug-eluting stents (DES) and drug-coated balloons (DCB) that transfer paclitaxel to the vessel wall during revascularization have been added to the suite of tools available to interventionists, helping to prevent restenosis after treatment. There have been a number of randomized controlled studies (RCT) showing the efficacy of the endovascular treatment with drug-coated balloons (DCB) in the femoropopliteal artery lesions. However, these studies have been carefully designed, and most of them have excluded long-length lesions and severely calcified lesions. In addition to being used alone in the real word, drug-coated balloons (DCB) are also used in combination with stents or debulking devices, but in these randomized controlled studies (RCT) they are only compared with standard percutaneous transluminal angioplasty (PTA). Therefore, the investigators initiated this study, which is a prospective, multicenter, observational real-world study of short and long-term outcome in endovascular treatment of femoropopliteal arterial occlusive lesions with DCB. It is estimated that 1200 patients with chronic femoral popliteal artery occlusion were enrolled in the group at 8 centers in China in two years. The follow-up would be conducted at 1, 3, 6, 12, 18, 24, 36 and 48 months after the operation to assess the efficacy and safety of the endovascular treatment with drug-coated balloons (DCB) in the femoropopliteal artery lesions.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 2000
Est. completion date February 1, 2027
Est. primary completion date February 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Rutherford grade 2-5. 2. Femoral popliteal artery stenosis or occlusion, a clear outflow tract no less than 10cm long at the distal end of the knee should be continuous with a clear outflow tract under the ankle. 3. Patients who understand the purpose of this study, volunteer to participate in the experiment, sign informed consent and are willing to follow up. 4. The guide wire needs to pass through the lesion. 5. Life expectancy> 24 months. 6. Patients with thrombosis of the lower extremities, patients who received drug-coated balloon (DCB) intervention after thrombus removal through mechanical thrombus removal, percutaneous catheter thrombolysis, and thrombus removal. 7. Patients who have received DCB intervention for both lower limbs can be enrolled in the group according to the intracavitary treatment time. 8. There is at least one continuous infrapopliteal outflow artery or obtained through intravascular reconstruction. 9. For combined aortic iliac artery disease, the blood flow can be recanalized after intravascular reconstruction without residual stenosis exceeding 50%. Exclusion Criteria: 1. Patients with stroke, cerebral hemorrhage, gastrointestinal hemorrhage or myocardial infarction within 3 months before enrollment. 2. Patients who are known to be allergic to heparin, aspirin, other antiplatelet drugs, contrast agents, etc. 3. Patients who have participated in clinical trials of drugs or other medical devices that interfere with this clinical trial within the past 3 months. 4. Pregnant and lactating women. 5. Patients who are unable or unwilling to participate in this trial. 6. Patients with Berg's disease. 7. Patients who have undergone arterial bypass on the treatment side.

Study Design


Intervention

Device:
Drug-coated Balloon
To observe the effectiveness and safety of the drug-coated balloon in the treatment of lower extremity arteriosclerosis obliterans of the femoral popliteal artery segment.

Locations

Country Name City State
China Xuanwu Hospital Capital Medical University Beijing
China Hospital of Chengdu University of Traditional Chinese Medicine Chengdu
China Hangzhou First People's hospital of Medical College of Zhejiang University Hangzhou
China the First Affiliated hospital of Medicine College of Zhejiang University Hangzhou
China Qingdao Haici hospital affiliated to Qingdao University Qingdao
China Renji Hospital of Shanghai Jiaotong University Shanghai
China Zhongshan Hospital of Fudan University Shanghai
China the second Affiliated Hospital of Medical College of Suzhou University Suzhou
China Zibo Feng Wuhan Hubei

Sponsors (8)

Lead Sponsor Collaborator
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology Chengdu University of Traditional Chinese Medicine, First People's Hospital of Hangzhou, Qingdao University, RenJi Hospital, Second Affiliated Hospital of Suzhou University, Xuanwu Hospital, Beijing, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Freedom from clinically-driven target lesion revascularization(CD-TLR) rate at post-interventional Clinically-driven target lesion revascularization (CD-TLR) is defined as any re-intervention within the target lesion due to symptoms or drop of ankle brachial index (ABI) of =20% or >0.15 when compared to post-procedure baseline. 48 months
Primary Major adverse events Operation-related acute thrombosis, arterial embolism, major amputation and all-cause mortality. 48 months
Secondary Changes of the patency rate of target lesions at post-interventional The patency rate of target(Femoropopliteal) lesions would be determined by vascular ultrasound,Restenosis would be diagnosed if the peak systolic velocity ratio(PSVR)=2. 5. 1 month, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months
Secondary Technical success rate Successfully revascularize the target vessel. The residual stenosis is <30% and there is no acute thrombosis occurred in the target vessel within 1 week post-operation. 1 week
Secondary Vascular quality of life questionnaire(VascuQol) The VascuQol was designed as a questionnaire containing five domains: pain (4 items), symptoms (4 items), activities (8 items), social (2 items), and emotional (7 items) to evaluate Health related quality of life (HRQL). Every item has seven response options, with scores ranging from 1 to 7. A total score is the sum of all 25 item scores divided by 25.And both the total score as well as the domain scores range from 1 (worst HRQL) to 7 (best HRQL).The lower the value, the poorer the quality of life. 1 month, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months
Secondary The patient's ulcer healing Ulcer healing in patients with Rutherford grade 5 1 month, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months
Secondary Freedom from clinically-driven target lesion revascularization(CD-TLR) rate at post-interventional Clinically-driven target lesion revascularization (CD-TLR) is defined as any re-intervention within the target lesion due to symptoms or drop of ankle brachial index (ABI) of =20% or >0.15 when compared to post-procedure baseline. 1 month, 3 months, 6 months, 12 months, 24 months, 36 months
Secondary Major adverse events Operation-related acute thrombosis, arterial embolism, major amputation and all-cause mortality. 1 month, 3 months, 6 months, 12 months, 24 months, 36 months
See also
  Status Clinical Trial Phase
Completed NCT02837744 - Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
Completed NCT02214082 - Safety of Same Day Discharge After Elective Percutaneous Coronary Intervention N/A
Recruiting NCT00370578 - Aspiration Device in Myocardial Infarction Trial N/A
Recruiting NCT02276846 - Palpitate-Eluting Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesion Evaluated by OCT N/A
Recruiting NCT01080638 - Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction. Phase 4
Completed NCT03673254 - Evaluation of Practices and Prognostic Factors of Percutaneous Coronary Interventions (PCI) of Calcified Complex Lesions Using Rotational Atherectomy Device.
Completed NCT01180517 - The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations Phase 4
Completed NCT01249027 - XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
Completed NCT00399646 - Evaluation of the Metricath Gemini System, a Device Intended to Make Arterial Measurements and Perform Angioplasty Dilations. Phase 2
Recruiting NCT05113407 - Observatory on the Use of the Shockwave Medical C2 Coronary Lithotripsy System in the General Population in France.
Completed NCT04445480 - Popliteal Block for Lower Limb Angioplasty N/A
Completed NCT02722213 - Mindfulness & Stress Management Study for Cardiac Patients N/A
Completed NCT00858715 - Resistance to Antithrombotic Therapy N/A
Recruiting NCT04325867 - Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19 N/A
Completed NCT01174472 - Drug Eluting Balloon Angioplasty for Dialysis Access Treatment Phase 2/Phase 3
Terminated NCT00289601 - Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty Phase 4
Completed NCT00715416 - PTA vs. Primary Stenting of SFA Using Self-Expandable Nitinol Stents Phase 4
Terminated NCT00437905 - Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial Phase 4
Completed NCT01894152 - XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
Completed NCT00808717 - Efficacy of High Dose atorvaSTATIN Loading Before Primary Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction (STATIN STEMI) Phase 4